Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1781-1800 of 3,900 trials

Hallux Valgus Surgery: Ropivacaine Ankle Block Study

We are investigating how different strengths of ropivacaine affect pain relief and recovery in patients undergoing hallux valgus repair surgery. This study aims to find the best concentration for effective anesthesia and reduced opioid use.

Bunion (Hallux Valgus)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteOrthopedics and TraumatologyOtolaryngology

Pancreatic Cancer: Personalized FOLFIRINOX Dosing Study

We are exploring how personalized dosing of the chemotherapy drug 5-FU affects safety and treatment outcomes in pancreatic cancer patients. This study aims to find the best dosing strategy to improve effectiveness and minimize side effects.

Pancreatic Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

High-Risk Medulloblastoma: New Treatment Approaches

We are exploring whether new radiotherapy and chemotherapy methods improve outcomes for children and adults with high-risk medulloblastoma. The study also looks at the long-term effects of these treatments on patients' health and quality of life.

Medulloblastoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncologyPediatrics

Rhabdomyosarcoma: New Treatment Combinations

We are studying new chemotherapy and radiotherapy options for children and adults with Rhabdomyosarcoma. The goal is to see if these new treatments improve outcomes compared to standard therapies.

RhabdomyosarcomaSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncologyPediatrics

Systemic Lupus Erythematosus: Obexelimab Study

We are studying a new medication, Obexelimab, for patients with systemic lupus erythematosus to see if it can lower disease activity and reduce fatigue. This trial compares its effects to a placebo treatment.

Systemic Lupus Erythematosus6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Intranasal COVID-19 Vaccine: LVT-001

We are studying a new intranasal booster vaccine for COVID-19 to see if it is safe and more effective than the standard mRNA vaccine. This trial is for healthy adults who want to help improve COVID-19 vaccination strategies.

COVID-191-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInfectious Diseases

Dementia: New Treatments for Agitation

We are exploring whether certain psychotropic medications can help reduce agitation in dementia patients who haven't responded to standard treatments. The study also examines potential side effects and personalized treatment methods.

Agitated BehaviorDementia≤3 monthsMonitoring phase (IV)Investigational MedicinesNeurologyPsychiatry

Ovarian Cancer: 5-ALA Imaging Study

We are testing a dye called 5-ALA to see if it helps surgeons find ovarian cancer tumors that regular methods might miss. This study aims to improve tumor detection during surgery.

Ovarian Cancer≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsOncologyOtolaryngology

Kidney Transplant Rejection: INTERCEPT Study

We are studying whether adding TCZ to standard treatment helps kidney transplant recipients with chronic rejection maintain better kidney function. The trial also looks at the safety of this treatment and its effects on overall health.

Chronic Active Antibody-Mediated Rejection>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology

Glioma Treatment Study: Temozolomide and Lomustine

We are testing a combination of chemotherapy and radiotherapy for patients with newly diagnosed grade 2 or 3 glioma. The goal is to see if this approach improves survival compared to standard treatments.

Newly Diagnosed Glioma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Parkinson's Disease: New Approaches to Levodopa Resistance

We are studying whether the medication apomorphine or the antibiotic rifaximin can help people with Parkinson's disease who struggle with levodopa treatment. This trial aims to improve their symptoms and overall treatment response.

Parkinson's Disease6-12 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementInternal MedicineNeurology

Acute Heart Failure: Diuretic Treatment Study

We are investigating the best diuretic strategies for patients with acute heart failure and volume overload. This study aims to improve treatment options for those at risk of diuretic resistance.

Acute Heart Failure>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteCardiologyInternal Medicine

Denosumab: Impact on Muscle Strength and Insulin Sensitivity

We are studying whether denosumab can improve muscle strength and insulin sensitivity in participants. This trial compares its effects to a placebo to understand its potential benefits.

Diabetes MellitusPostmenopausal Osteoporosis6-12 monthsMonitoring phase (IV)Standard MedicinesEndocrinologyHepatologyInternal Medicine

Acute Myeloid Leukemia: Venetoclax and Azacitidine Treatment

We are studying whether a combination of venetoclax and azacitidine can help clear residual disease in AML patients before a stem cell transplant. This trial also looks at the safety and effectiveness of this treatment approach.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Soft Tissue Sarcoma: Oral Cyclophosphamide vs Doxorubicin

We are comparing the effectiveness of oral cyclophosphamide and doxorubicin in treating elderly patients with advanced soft tissue sarcoma. The goal is to find out which treatment may lead to better outcomes and fewer side effects.

Soft Tissue SarcomaConfirmation phase (III)No PlaceboStandard MedicinesOncology

Advanced Solid Tumors: BT5528 Treatment Study

We are testing a new drug, BT5528, for patients with advanced solid tumors that express EphA2. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Malignant Solid Tumor1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Chronic Migraine: Eptinezumab for Teens

We are studying whether eptinezumab can help reduce the number of migraine days in adolescents aged 12 to 17 with chronic migraine. This trial compares the medication to a placebo to assess its effectiveness.

Migraine3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Zanamivir for Infants with Complicated Influenza

We are studying how safe and effective intravenous zanamivir is for hospitalized infants under 6 months with complicated influenza. This research aims to understand how the drug works in young children.

Human Influenza>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesPediatrics

HIV Prevention: Long-Acting Injectable Cabotegravir vs. Daily Oral Medication

We are studying whether a long-acting injectable form of cabotegravir is more effective than daily oral medication for preventing HIV in men who have sex with men. This trial aims to understand how well each option works over time and their impact on participants' health and behaviors.

HIV Prevention>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesInternal Medicine

Andersen-Tawil Syndrome: Flecainide Therapy Study

We are exploring whether flecainide alone or in combination with other medications is more effective for managing heart rhythm issues in patients with Andersen-Tawil syndrome and multifocal ectopic contractions.

Andersen-Tawil SyndromeMultifocal Ectopic Purkinje-related Premature Contractions≤3 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiology